The FDA approval for the use of a suspension lentiviral vector in the manufacturing of Abecma, a product co-developed with 2Seventy Bio, is likely to streamline the production process, potentially reducing costs and improving the scalability of Abecma production. This could lead to increased profitability for Bristol Myers Squibb in the short term as it may enhance the production efficiency and possibly the market supply of Abecma.

2Seventy Bio's involvement in the development and FDA approval of a new manufacturing process for Abecma, in collaboration with Bristol Myers Squibb, is likely to positively impact its market position by highlighting its capability for innovation and successful partnerships. This could attract further collaborations and investments, enhancing its short-term growth prospects.